PDS Biotechnology (NASDAQ:PDSB) Earns Buy Rating from HC Wainwright

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $21.00 price objective on the stock.

Separately, B. Riley decreased their price target on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, PDS Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Trading Down 2.4 %

NASDAQ PDSB opened at $1.23 on Thursday. The firm has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $2.28. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a one year low of $1.13 and a one year high of $5.00. The firm has a market cap of $46.98 million, a price-to-earnings ratio of -1.06 and a beta of 1.68.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PDSB. XTX Topco Ltd raised its holdings in PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after purchasing an additional 47,528 shares in the last quarter. Geode Capital Management LLC raised its holdings in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after purchasing an additional 37,142 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in PDS Biotechnology during the fourth quarter worth approximately $26,000. Virtu Financial LLC acquired a new stake in PDS Biotechnology during the fourth quarter worth approximately $89,000. Finally, Blair William & Co. IL raised its holdings in PDS Biotechnology by 29.4% during the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after purchasing an additional 35,757 shares in the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.